Prestige BioPharma Limited

KSE 950210.KS

Prestige BioPharma Limited Shareholders' Equity for the year ending June 30, 2024: USD 317.90 M

Prestige BioPharma Limited Shareholders' Equity is USD 317.90 M for the year ending June 30, 2024, a -6.66% change year over year. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Prestige BioPharma Limited Shareholders' Equity for the year ending June 30, 2023 was USD 340.59 M, a 2.48% change year over year.
Prestige BioPharma Limited Shareholders' Equity for the year ending June 30, 2022 was USD 332.34 M, a -34.32% change year over year.
Prestige BioPharma Limited Shareholders' Equity for the year ending June 30, 2021 was USD 505.97 M, a 342.38% change year over year.
Prestige BioPharma Limited Shareholders' Equity for the year ending June 30, 2020 was USD 114.37 M, a 128.29% change year over year.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

KSE: 950210.KS

Prestige BioPharma Limited

CEO	Ms. So-Yeon Park
IPO Date	Feb. 9, 2021
Location	Singapore
Headquarters	21 Biopolis Road
Employees	66
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Plastics Vaccines

Description

Prestige BioPharma Limited, a biopharmaceutical company, engages in the research, development, and marketing of biosimilars and new antibody therapeutics in the Asia Pacific. The company primarily engages in the development of new and similar antibody drugs for solid tumor, pancreatic cancer, breast cancer, gastric cancer, and arthritis. It is also developing vaccines for COVID-19 virus. The company was incorporated in 2015 and is headquartered in Singapore.

Key trends

Past 5 years